Temasek agreed to invest $250m in BioNTech, a clinical-stage biotechnology company. The investment includes $139m in ordinary shares and $112m in 4-year mandatory convertible notes. “We are pleased to welcome Temasek onboard as a new shareholder. We believe their long-term investment approach, global presence, and deep experience in the biotechnology field are a good fit with our vision to build a leading global biopharmaceutical company,” Ugur Sahin, BioNTech CEO and Co-Founder.